Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
When you say "MACD shows how they were holding it down" you mean disguised accumulation/covering, I assume.
If his stock is restricted then he still owns it, which negates the premise of your question of "why would he leave just when he's supposedly about to get rich?" You should really try to make more sense with your manipulation attempts, OB. Your employer is not getting its money's worth.
Well, breaking through the 9.40 range would have been better, but ... If you're a trader. Doesn't matter much to us investors either way.
They prevented the pps from breaking through the moving average and so traders are bringing it down.
You got it, Blue. The action in the indexes and in ADXS sure looks like carefully engineered, orderly covering. When they are done, there we go.
Mastiff, clearly North America and Europe are huge markets. Europe in particular is attractive to BPs due to the fast-moving EU approval progress. There may be less people in the U.S. and Asia, but they have money to spend. The rights to Canada were definitely licensed as part of the Knight deal.
How has ADXS given away rights to largest markets for cervical cancer? There is no deal for the U.S., Europe, etc. I have no clue what is the status of rights for Asian markets, due to the mystery of Biocon. Anyone?
DOC should be fired for causing this horrible development of dosing the first patient withOUT also arranging for the pps to take off in response. He should have instructed his secret band of shady traders to run the stock up on the news, using HFT and spam e-mails.
Interesting report on the genomic lung cancer therapy. NEO could be the fledgling phase of a technology that could actually be called a "cure" at some point. Exciting times. Btw, a large percentage of my posts get deleted. Some I cannot even figure out why.
Husker, that has been my prediction all along. My money is on Amgen. NEO is so perfectly in Amgen's wheelhouse, and they really need the rights to the base indications as well. ADXS will eventually be part of Amgen. And Amgen may buy the whole thing sooner than anyone expects, because it will not risk losing indications to other BPs. It will want/need the whole enchilada.
MM's engineering a consolidation.
Understood, Fbg. ADXS will probably never develop a distribution arm. When I said "go it alone" I really meant "remain an independent company," i.e., "not agree to a buyout." Although Although ADXS could theoretically remain independent and continue running R&D and manufacturing, with licensing deals for marketing and distribution.
DOC will take the money and run when it is offered. If ADXS goes it alone after approval his money will remain largely locked up.
I almost forgot about Chinaman. He was a good guy too, quite a character, and he definitely had a bit of a trader mentality, so I can see him just moving on, as you say. 2017 will be a good year. I think the short suppressors are just looking for the right catalyst and then they will change their tune and this thing will roll. They are already soft-preparing for it, it seems.
J&E was, unfortunately, driven away from the other board I frequented, by shorts and fake longs who correctly viewed his stellar positive analysis as a threat to their interests.
J&E is an ace. I'm sorry he/she is no longer around.
Absolutely, Fb. It's not a matter of "if," it's a matter of "when." And the same parties who have been shorting and suppressing will use their nefarious methods in the opposite direction. Personally, I think they have already begun, slowly but surely.
FBG, the mm's obviously are dealers, buying and selling at the same time, with a spread. When they deal from the shorts side they are not maintaining any inventory of shares to sell to buyers. They are fulfilling demand for shares by shorting them to the buyers. Thus, they maintain a large short position which, of course, means that they don't want to see the market rise too much because then they could get stuck. So they are suppressing the pps. But they can't let their short position grow too large, so they periodically cover some when the price gets low enough. Then when the pps rises they repeat the cycle. That is why they have us trapped in a fairly well-defined range.
When the mm's stop dealing from the short side, that's when this thing will really reverse.
Lowest short interest since July. Nice.
I figured. Thanks, Phyto.
You can probably figure out what the CTO document is by the context. Someone just has to go figure out from the 10-k what Exhibit 10.57 relates to. Most likely it is money terms related to the Amgen deal, if I had to guess. Milestones, royalty percentages, etc. Or, it could be the identity of the private placement purchaser in August.
The CTO must be something good. CTOs are not used for negative information. Their purpose is to protect a company's trade secrets. You cannot hide bad developments with a CTO.
Lol. They are taking their bacteria and going home.
Agreed. Would actually require an 8-k.
Aren't there possible reasons for ADRO suspending a trial aside from an FDA hold? By the way, I notice that the FDA website doesn't include patients with implants under the exclusion criteria. I wonder if that is the reason for the suspension.
Easy, by any chance do you drink a lot of coffee? lol
You're right, FBG. I had a brain fart on that one. Lower 5% threshold is merely for Rule 13.
Niiiice. Blackrock upping their stake. Now an insider.
Traders look for any excuse to act in concert without expressly agreeing to it. So when they see an imminent bad sector day they all hop on board, and short the individual stocks. Actually, I think ADXS may be part of the XBI, but not the IBB.
The sector action is often stronger than individual news. Sector taking a hit today. That's all it is.
What is the date of the presentation?
There is a lot of leeway in the terms "adequate safety and effectiveness." Agency's are generally given fairly broad discretion, i.e. Rulemaking authority. Congress generally sets a rough framework with general terms and then defers to the agency's superior expertise on how to implement it.
Well, you don't really know for sure when covering is occurring. It is largely interpretative. But "real" trading in this stock is very light (as opposed to the robots trading 56 shares back and forth to each other all day), so when there is any significant real buying (or selling) it sticks out pretty clearly in the price/volume action, as he noted.
Bill, not necessarily today, but in general I agree. Short covering.
Yes, something needs to change. What needs to change is the shorts, who are living on borrowed time and borrowed shares. They cannot manipulate and suppress forever. They will either decide to stop on their own or be forced to stop by significant accumulation, which is not something their robots can manipulate against. However, none of this has anything to do with Dan or the state of the company. Except that, obviously, big news will likely be the cause of the "real" pps reversal.
That is a possibility, Bourbon. However, if that does happen then something went wrong substantively to justify the low valuation. No evidence of that occurring.
In what way has he underperformed, substantively? I thought everyone was happy with the clinical trial progress, possible early EU, and the Amgen deal, etc. What other "performance" is within his direct control? Answer: nothing.
I hear you, Bourbon, but the reality is that they probably would have taken it down exactly to where they actually did take it down, regardless of the private placement at 13.50.
Deck, you referring to the Gerritsen article Petit posted? Seems to me that he simply posted it as a matter of general interest.